To further identify optimal tumor contexts susceptible to bi-steric mTORC1-selective inhibition we focused on breast cancers where this pathway is commonly activated by mutation in upstream regulators such as PIK3CA and PTEN. This evidence concerns the gene PIK3CA and breast carcinoma.